Table 2.
Trials with Immune Checkpoint Inhibitors.
| Drug | Combination | Status | Clinical Trial ID |
|---|---|---|---|
| Nivolumab | Single agent | Phase III | NCT02105636 |
| Varlilumab | Phase I/II | NCT02335918 | |
| INCB24360 | Phase I/II | NCT02327078 | |
| PLX3397 | Phase I | NCT02526017 | |
| Single agent | Phase I/II | NCT02488759 | |
| Standard therapy | Phase I | NCT02764593 | |
| Ipilimumab | Phase I/II | NCT03003637 | |
| Ipilimumab | Phase II | NCT02823574 | |
| Ipilimumab | Phase III | NCT02741570 | |
| Single agent/ipilumamb | Phase II | NCT02919683 | |
| Epacadostat | Phase I/II | NCT02327078 | |
| Single agent vs Combination(Ipilumamb, BMS‐986016, Daratumamb) | Phase I/II | NCT02488759 | |
| IPI549 | Phase I | NCT02637531 | |
| TAK659 | Phase I | NCT02834247 | |
| Enadenotucirev | Phase I | NCT02636036 | |
| Ipilimumab | Phase II | NCT03097939 | |
| Pembrolizumab | ACP‐196 | Phase II | NCT0454179 |
| Single agent | Phase III | NCT02252042 | |
| Single agent | Phase III | NCT02358031 | |
| INCB24360 | Phase II | NCT02178722 | |
| PLX3397 | Phase I/II | NCT02452424 | |
| Single agent | Phase II | NCT02296684 | |
| MGA271 | Phase I | NCT02475213 | |
| Single agent | Phase II | NCT02255097 | |
| Single agent | Phase II | NCT02769520 | |
| Talimogene Laherparepvec | Phase I | NCT02626000 | |
| Cisplatin | Phase II | NCT02641093 | |
| Single agent | Phase II | NCT02289209 | |
| Cisplatin | Phase II | NCT02777385 | |
| Single agent | Phase II | NCT02609503 | |
| Acalabrutinib | Phase II | NCT02454179 | |
| Cisplatin | Phase III | NCT03040999 | |
| Single agent | Phase II | NCT02841748 | |
| Single agent/cisplatin/carboplatin/5‐FU | Phase III | NCT02358031 | |
| Docetaxel | Phase I/II | NCT02718820 | |
| SD‐101 | Phase I/II | NCT02521870 | |
| Single agent | Phase II | NCT03057613 | |
| Chemoradiotherapy | Phase I | NCT02819752 | |
| Single agent | Phase III | NCT02252042 | |
| Single agent | Phase II | NCT02892201 | |
| Cisplatin, IMRT | Phase I | NCT02775812 | |
| Docetaxel, 5‐FU, Cisplatin | Phase II | NCT03114280 | |
| Single agent | Phase II | NCT03085719 | |
| Vorinostat | Phase I/II | NCT02538510 | |
| Single agent | Phase II | NCT02296684 | |
| Single agent | Phase I | NCT02318771 | |
| Single agent | Phase II | NCT02707588 | |
| Cetuximab | Phase II | NCT03082534 | |
| Cisplatin | Phase I/II | NCT02759575 | |
| RecombinantEphB4‐HSA fusion protein | Phase II | NCT03049618 | |
| Levatinib | Phase I/II | NCT02501096 | |
| PLX3397 | Phase I/II | NCT02452424 | |
| Levatinib | Phase I | NCT03006887 | |
| Single agent | Phase I | NCT01848834 | |
| Single agent | Phase II | NCT02644369 | |
| Atezoluzmab | Obintuzumab | Phase I | NCT02174172 |
| Single agent | Phase I | NCT01375842 | |
| PF‐0502566 | Pembrolizumab | Phase I | NCT02179918 |
| Urelumab | Cetuximab | Phase I | NCT02110082 |
| MEDI4736 | Tremelimumab | Phase III | NCT02369874 |
| AZD9150/AZD5069 | Phase I/II | NCT02499328 | |
| Single agent | Phase II | NCT02207530 | |
| ADXS 11–001 | Phase I/II | NCT02291055 | |
| Mogamulizumab | Phase I | NCT02301130 | |
| Tremelimumab | Mogamulizumab | Phase I | NCT02301130 |
| Ipilumamab | Cetuximab and XRT | Phase I | NCT01935921 |
| MGA271 | Phase I | NCT02381314 | |
| PF‐4518600 | Single agent | Phase I | NCT02315066 |
| AZD17751(Wee1 Inhibitor) | Single agent | Phase I | NCT01748825 |